← Eichor
Condition: T Non Hodgkin Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: T Non Hodgkin Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Phase 1 · 1 location(s) · The Third Affiliated Hospital of Southern Medical University · NCT06758713CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
Phase 1/Phase 2 · 2 location(s) · Uppsala University · NCT06002659Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06464861Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07225985Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06589089Novel Therapeutic Approach for Human T-cell Malignancies
Phase N/A · 2 location(s) · Istituto Oncologico Veneto IRCCS · NCT06600568Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Phase N/A · 2 location(s) · Emory University · NCT03501576Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell L
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07164560In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Phase 2 · 1 location(s) · Hrain Biotechnology Co., Ltd. · NCT05436223Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT06934382A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05757219Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT06207812huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07343934Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06793241Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Phase 1/Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT05480449Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Phase 2 · 1 location(s) · New York Medical College · NCT07013565A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Aibin Liang，MD，Ph.D. · NCT06734871Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-R
Phase 1/Phase 2 · 1 location(s) · Liping Dou · NCT07575971A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06446128A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of New
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06630091Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · 34 location(s) · Corvus Pharmaceuticals, Inc. · NCT06561048B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT03587844Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Zhujiang Hospital · NCT06902012Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.